Minerva Neurosciences Inc. (NASDAQ:NERV) rose 1.7% during mid-day trading on Friday . The company traded as high as $10.65 and last traded at $10.45, with a volume of 87,591 shares traded. The stock had previously closed at $10.28.

NERV has been the topic of a number of recent analyst reports. Zacks Investment Research downgraded Minerva Neurosciences from a “strong-buy” rating to a “hold” rating in a research report on Wednesday, April 20th. Jefferies Group began coverage on Minerva Neurosciences in a research note on Thursday, May 12th. They issued a “buy” rating and a $10.00 target price on the stock. Finally, JMP Securities increased their target price on Minerva Neurosciences from $10.00 to $17.00 in a research note on Thursday, May 26th.

The company’s 50-day moving average price is $10.87 and its 200-day moving average price is $6.94. The stock’s market cap is $292.27 million.

Minerva Neurosciences (NASDAQ:NERV) last posted its earnings results on Tuesday, May 3rd. The biopharmaceutical company reported ($0.29) EPS for the quarter, topping analysts’ consensus estimates of ($0.33) by $0.04. Equities analysts forecast that Minerva Neurosciences Inc. will post ($1.05) EPS for the current year.

In related news, Director David Kupfer bought 55,635 shares of the business’s stock in a transaction on Tuesday, June 21st. The stock was acquired at an average price of $10.84 per share, with a total value of $603,083.40. Following the transaction, the director now owns 209,188 shares in the company, valued at approximately $2,267,597.92. The purchase was disclosed in a legal filing with the Securities & Exchange Commission, which is accessible through this link.

Minerva Neurosciences, Inc is a clinical-stage biopharmaceutical company. The Company is focused on the development and commercialization of a portfolio of product candidates to treat patients suffering from central nervous system (CNS) diseases. The Company’s product portfolio include MIN-101 for the treatment of schizophrenia; MIN-117 for the treatment of major depressive disorder (MDD); MIN-202 (also known as JNJ-42847922) for the treatment of insomnia disorder and adjunctive MDD, and MIN-301 for the treatment of Parkinson’s disease.

Get Analysts' Upgrades and Downgrades Daily - Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.